Benzinga · Aug 17, 2026
UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49
UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $45 to $49.
AC
NASDAQ · ACAD
ACADIA Pharmaceuticals Inc.
Healthcare · Biotechnology
$29.73
Up+$0.15 (+0.51%)
Updated Aug 28, 2026, 7:51 AM
SID Score
7.5/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 4.16B
- P/E ratio
- 10.64
- Dividend yield
- 0.00%
- 52-week range
- $19.89 – $30.96
- Volume
- 879.37K
- Avg. volume
- 1.45M
Price performance
ACAD price history
1M range · 21 trading sessions · Daily adjusted prices
ACAD closed at $29.73 after 21 trading sessions, up 11.98% for the selected period.
- Last close
- $29.73
- Period change
- +11.98%
- Period low
- $25.61
- Period high
- $30.57
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $29.26 | $29.83 | $29.15 | $29.73 | 879.37K |
| Aug 26, 2026 | $30.36 | $30.3799 | $29.28 | $29.58 | 1.34M |
| Aug 25, 2026 | $30.14 | $30.76 | $29.845 | $30.57 | 1.52M |
| Aug 24, 2026 | $29.50 | $29.775 | $29.15 | $29.65 | 1.49M |
| Aug 21, 2026 | $29.08 | $29.615 | $28.80 | $29.50 | 1.09M |
| Aug 20, 2026 | $30.00 | $30.00 | $28.95 | $29.04 | 1.32M |
| Aug 19, 2026 | $30.66 | $30.96 | $30.07 | $30.21 | 2.29M |
| Aug 18, 2026 | $29.14 | $30.25 | $29.05 | $30.18 | 2.05M |
| Aug 17, 2026 | $28.63 | $29.03 | $28.21 | $29.01 | 1.12M |
| Aug 14, 2026 | $28.26 | $28.425 | $27.90 | $28.24 | 1.06M |
| Aug 13, 2026 | $29.75 | $29.75 | $28.36 | $28.38 | 1.51M |
| Aug 12, 2026 | $29.18 | $29.85 | $28.83 | $29.45 | 1.41M |
| Aug 11, 2026 | $29.565 | $29.76 | $29.095 | $29.41 | 1.35M |
| Aug 10, 2026 | $29.00 | $29.65 | $29.00 | $29.39 | 2.73M |
| Aug 7, 2026 | $28.57 | $29.29 | $28.20 | $29.21 | 1.78M |
| Aug 6, 2026 | $28.85 | $29.48 | $28.32 | $28.45 | 3.05M |
| Aug 5, 2026 | $27.955 | $29.165 | $27.80 | $28.80 | 4.55M |
| Aug 4, 2026 | $25.66 | $27.23 | $25.55 | $27.15 | 2.44M |
| Aug 3, 2026 | $25.96 | $26.105 | $25.43 | $25.61 | 1.37M |
| Jul 31, 2026 | $26.44 | $26.44 | $25.345 | $25.87 | 1.53M |
| Jul 30, 2026 | $26.13 | $26.58 | $25.87 | $26.55 | 1.3M |
Latest ACAD news
The latest Smart Investors Daily articles mentioning ACAD.
Stock researchCompany · Overview
ACAD research
Overview
Company profile and research snapshot.
Company profile
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $28.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | Citigroup | Buy | — |
| Aug 25, 2026 | Morgan Stanley | Equal-Weight | — |
| Aug 25, 2026 | Deutsche Bank | Buy | — |
| Aug 17, 2026 | UBS | Buy | — |
| Aug 12, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 12, 2026
Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $38 to $41.
Benzinga · Aug 10, 2026
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $35 to $39.
Benzinga · Aug 5, 2026
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25
Oppenheimer analyst Matthew Hershenhorn maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and raises the price target from $23 to $25.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
